HEAD AND NECK SQUAMOUS CELL CARCINOMA
Clinical trials for HEAD AND NECK SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new HEAD AND NECK SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Can quitting smoking change cancer's environment? new study explores.
Disease control CompletedThis study tested a special smoking cessation program (ETIP) in 19 adults with head and neck or lung cancer. The program combined counseling, medication, and nicotine replacement to help patients cut down or quit smoking. Researchers also checked if reducing smoking changed the t…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: NA • Sponsor: Thomas Jefferson University • Aim: Disease control
Last updated May 26, 2026 06:12 UTC
-
Could a common ED drug boost cancer immunotherapy?
Disease control CompletedThis study tested whether adding tadalafil (a drug often used for erectile dysfunction) to pembrolizumab (an immunotherapy) could help control advanced head and neck cancer. Seven adults with recurrent or metastatic disease participated. The goal was to check safety and see if th…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: University of California, San Diego • Aim: Disease control
Last updated May 26, 2026 06:11 UTC
-
New combo aims to unleash immune system on tough cancers
Disease control CompletedThis early-phase study tested whether adding L-NMMA to the immunotherapy drug pembrolizumab is safe for people with several advanced cancers, including melanoma, lung cancer, and others. The goal was to see if blocking a signal that protects cancer cells could help the immune sys…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: The Methodist Hospital Research Institute • Aim: Disease control
Last updated May 26, 2026 06:09 UTC
-
Double-Drug attack shows promise against tough head and neck cancers
Disease control CompletedThis study tested whether combining two approved cancer drugs, cetuximab and nivolumab, could help people with advanced head and neck cancer that had returned or spread. A total of 95 participants received the combination to see if it improved survival and shrank tumors. The goal…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated May 26, 2026 06:09 UTC
-
Promising combo targets tough cancers in early trial
Disease control CompletedThis study tested a combination of two drugs—sEphB4-HSA and pembrolizumab—in 42 people with advanced non-small cell lung cancer or head & neck cancer that had spread or returned. The goal was to see if the combo could shrink tumors better than standard treatments. Participants ha…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: University of Southern California • Aim: Disease control
Last updated May 26, 2026 06:07 UTC
-
Experimental cancer vaccine combo shows promise in small trial
Disease control CompletedThis early-phase trial tested a combination of four therapies to train the immune system to attack cancer. 17 adults with non-Hodgkin's lymphoma, metastatic breast cancer, or head and neck cancer received low-dose radiation, an immune cell booster (Flt3L), an immune activator (Po…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Disease control
Last updated May 26, 2026 06:06 UTC
-
New immunotherapy combo tested for head and neck cancer patients
Disease control CompletedThis study tested whether giving the immunotherapy drug durvalumab along with radiation works better than the standard cetuximab plus radiation for people with advanced head and neck cancer who cannot take the usual chemotherapy drug cisplatin. The trial enrolled 196 participants…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 06:03 UTC
-
New immune drug shows promise in early cancer trial
Disease control CompletedThis early-phase trial tested a drug called MEDI0562, which aims to boost the immune system's ability to fight cancer. It was given to 13 patients with advanced head and neck cancer or melanoma before their surgery. The main goal was to see if the drug safely activates the immune…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Providence Health & Services • Aim: Disease control
Last updated May 26, 2026 06:00 UTC
-
New drug RPH-002 tested against standard therapy in head and neck cancer
Disease control CompletedThis study tested a new drug called RPH-002 against the standard drug Erbitux in 118 people with advanced head and neck cancer that had spread or come back. The goal was to see how the body processes each drug and to compare their safety when used with chemotherapy. This is an ea…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: R-Pharm • Aim: Disease control
Last updated May 26, 2026 05:51 UTC
-
AI shrinks radiation targets, cuts side effects in head and neck cancer trial
Disease control CompletedThis study tested a new radiation approach for head and neck cancer that uses artificial intelligence to focus treatment only on cancerous lymph nodes, skipping healthy ones. 67 patients were enrolled to see if this reduces side effects without increasing the risk of cancer retur…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: University of Texas Southwestern Medical Center • Aim: Disease control
Last updated May 26, 2026 05:49 UTC
-
New drug combo shows promise for tough head and neck cancers
Disease control CompletedThis study tested a combination of two drugs, pembrolizumab and cetuximab, in 78 adults with advanced head and neck cancer that had spread or come back. The goal was to see if the combo could shrink tumors or slow the disease. Patients were grouped based on whether they had tried…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: University of California, San Diego • Aim: Disease control
Last updated May 26, 2026 05:48 UTC
-
New drug cocktail shows promise for three tough cancers
Disease control CompletedThis study tested a combination of two drugs (IO102-IO103 and pembrolizumab) as the first treatment for people with advanced lung, head & neck, or bladder cancer that has spread. The goal was to see if the combo could shrink tumors and delay cancer growth. A total of 63 patients …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: IO Biotech • Aim: Disease control
Last updated May 26, 2026 04:37 UTC
-
Supercharged immune cells take on Hard-to-Treat head and neck cancer
Disease control CompletedThis trial tested a new treatment for a type of head and neck cancer linked to the Epstein-Barr virus. Researchers took patients' own immune cells, engineered them to recognize and attack the virus on cancer cells, and also added a feature to block a common cancer defense. The st…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Xinqiao Hospital of Chongqing • Aim: Disease control
Last updated May 22, 2026 14:02 UTC
-
Supercharged immune cells take on HPV cancers in early trial
Disease control CompletedThis early-stage trial tested a new treatment for people with HPV-positive head and neck or cervical cancer that has spread or come back. The therapy uses a patient's own immune cells, engineered to recognize and attack HPV-infected cancer cells. Some cells were also modified to …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Xinqiao Hospital of Chongqing • Aim: Disease control
Last updated May 22, 2026 13:54 UTC
-
Yeast vaccine trains immune system to fight returning cancers
Disease control CompletedThis early-phase study tested a personalized vaccine made from yeast that is designed to teach the immune system to recognize and attack leftover cancer cells. It included 5 adults with different cancers who had already completed treatment aimed at curing their disease. The goal …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: NantBioScience, Inc. • Aim: Disease control
Last updated May 22, 2026 13:53 UTC
-
New pill shows promise against tough cancers in early trial
Disease control CompletedThis early-phase study tested a new daily pill called JAB-3312 in 40 adults with advanced solid tumors (like lung, colorectal, or breast cancer) that had stopped responding to standard treatments. The main goals were to find the safest dose and check for side effects. Researchers…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Jacobio Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated May 22, 2026 13:52 UTC
-
New drug combo shows promise in battling head and neck cancer
Disease control CompletedThis study tested a combination of two drugs, ramucirumab and pembrolizumab, in 43 people with advanced head and neck cancer that had spread or come back. The goal was to see if the combination was safe and could shrink tumors better than one drug alone. The trial found a safe do…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated May 22, 2026 13:51 UTC
-
New drug combo shows promise for tough head and neck cancer
Disease control CompletedThis study tested whether adding lenvatinib to pembrolizumab (a standard immunotherapy) helps people with advanced head and neck cancer that has come back or spread. 112 adults with a specific marker (PD-L1) received either the drug combo or pembrolizumab alone. The goal was to s…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
Immunotherapy combo shows promise against tough head and neck cancers
Disease control CompletedThis study tested a new treatment approach for people with advanced head and neck cancer that cannot be removed by surgery. The treatment combined the immunotherapy drug camrelizumab with chemotherapy and radiation, followed by camrelizumab alone. The goal was to see if this comb…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Chongqing University Cancer Hospital • Aim: Disease control
Last updated May 18, 2026 12:08 UTC
-
New drug combo shows promise against tough head and neck cancer
Disease control CompletedThis study tested whether adding lenvatinib to pembrolizumab helps people with advanced head and neck cancer that has come back or spread. About 511 adults with a specific type of head and neck cancer took part. The goal was to see if the combination shrinks tumors, delays cancer…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
Blood test may replace needle biopsy for some cancers
Diagnosis CompletedThis study tested whether a new blood test (liquid biopsy) can accurately find cancer biomarkers in patients with head and neck, lung, or skin cancer. 135 adults with advanced cancer provided blood and tumor tissue samples. The goal was to see if the blood test works as well as t…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Sponsor: Pharmassist Ltd • Aim: Diagnosis
Last updated May 11, 2026 20:39 UTC
-
Custom blood test could spot head and neck cancer relapse early
Knowledge-focused CompletedThis study looked at whether a personalized blood test can find tiny bits of tumor DNA (ctDNA) in patients with advanced head and neck cancer. Forty patients provided blood samples before surgery, after surgery, and during 18 months of follow-up. The goal was to see if tracking c…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: NA • Sponsor: Centre Henri Becquerel • Aim: Knowledge-focused
Last updated May 26, 2026 05:48 UTC
-
New MRI scan may forecast head and neck cancer relapse
Knowledge-focused CompletedThis study looked at whether a type of MRI called diffusion-weighted MRI (DW-MRI) can predict if head and neck cancer will come back after chemoradiotherapy. Researchers scanned 59 patients shortly after treatment and tracked them for up to a year. The goal was to see if early ch…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: NA • Sponsor: CHU de Reims • Aim: Knowledge-focused
Last updated May 20, 2026 12:03 UTC
-
Tumor biobank holds key to personalized head and neck cancer care
Knowledge-focused CompletedThis study collected tumor samples from 419 adults with head and neck cancer to create a biobank for future research. The goal is to use genetic information from these samples to better predict how each patient will respond to treatment. No direct treatment was given; the focus i…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Sponsor: Maastricht Radiation Oncology • Aim: Knowledge-focused
Last updated May 18, 2026 12:09 UTC